# Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

> **NCT00705653** · PHASE1 · COMPLETED · sponsor: **Progen Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** PG-11047

## Key facts

- **NCT ID:** NCT00705653
- **Lead sponsor:** Progen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705653, "Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00705653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*